

Ulcerative Colitis

**A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis**

**Trial Status**  
Completed

**Trial Runs In**  
23 Countries

**Trial Identifier**  
NCT04090411 TL1A,Tuscany  
2,2019-002698-74 B7541007

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT04090411 TL1A,Tuscany 2,2019-002698-74 B7541007**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years & ≤ 75 Years

**Healthy Volunteers**  
No

---